Efficacy of oral NAC and rectal indomethacin in prevention pancreatitis after ERCP

Phase 3

• Conditions: Pancreatitis.; Acute pancreatitis, unspecified; K85.9

• Registration Number: IRCT20201222049798N1
• Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 5 January 2021

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 280

Inclusion Criteria

Patients who candidate for endoscopic retrograde cholangiopancreatography (ERCP) including patients with jaundice due to biliary obstruction and imaging findings indicating pancreatic duct obstruction
Consent to participate in the study

Exclusion Criteria

History of pancreatitis before ERCP
Uncontrolled diabetes,
Triglyceride more than 1000 mg/d

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of pancreatitis. Timepoint: 24 hours after ERCP. Method of measurement: Based on the amount of amylase increase (more than 276 IU/di) and the presence of abdominal pain and patient report of abdominal pain after ERCP.;Severity of pancreatitis. Timepoint: Duration of hospitalization. Method of measurement: Based on the number of hospitalization days (mild pancreatitis: hospitalization less than 4 days, moderate pancreatitis: 4 to 10 days; severe pancreatitis: more than 10 days).